ArticleCancer research and treatment2016

Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors.

Do-Youn Oh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.